Literature DB >> 7514222

Pharmacological evidence that nitric oxide mediates the antinociception produced by muscarinic agonists in the rostral ventral medulla of rats.

E T Iwamoto1, L Marion.   

Abstract

The present study was designed to characterize the antinociception produced by the administration of a muscarinic agonist, (+)-cis-methyldioxolane, into the rostral ventral medulla (RVM) of male Sprague-Dawley rats. Seven days after the implantation of 25-gauge stainless-steel guide cannulae, animals were injected with graded doses of (+)-cis-methyldioxolane, and antinociception was assessed by using the 52 degrees C hot-plate and tail-flick tests in a single-blind design. (+)-cis-Methyldioxolane produced dose-related hot-plate and tail-flick antinociception for 30 to 45 min peaking 5 to 10 min after RVM injection. The ED50 values of (+)-cis-methyldioxolane in the hot-plate and tail-flick tests were 2.4 and 1.7 nmol, respectively. Five-minute preinjections with 0.35 nmol of the muscarinic M1 receptor blocker pirenzepine competitively antagonized the antinociception produced by (+)-cis-methyldioxolane. The antinociception produced by RVM injections of the muscarinic M2 receptor blocker methoctramine was additive to the antinociceptive effects of (+)-cis-methyldioxolane when the two antinociceptive effects of (+)-cis-methyldioxolane when the two agents were combined. Twenty four-hour pretreatment of the RVM with the irreversible muscarinic receptor antagonist 4-diphenylacetoxy-N-[2-chloroethyl]-piperidine mustard blocked the antinociceptive effects of (+)-cis-methyldioxolane completely. Administration of 6 nmol of the nitric oxide synthase inhibitor L-NG-nitroarginine into the RVM competitively antagonized the antinociception produced by (+)-cis-methyldioxolane and (+)-muscarine in the hot-plate and tail-flick tests. Pretreatment with 100 nmol of L-arginine, but not D-arginine, significantly reversed the inhibitory effects of L-NG-nitroarginine on (+)-cis-methyldioxolane-produced antinociception. Pretreatment with 100 nmol of the guanylyl cyclase inhibitor methylene blue into the RVM profoundly antagonized the antinociception produced by (+)-cis-methyldioxolane. Neither buffer L-NG-nitroarginine, L-arginine-D-arginine or methylene blue altered hot-plate or tail-flick nociception when injected alone into the RVM. In contrast, either dibutyryl cyclic GMP or 8-bromo cyclic GMP, membrane-permeable cyclic GMP analogs, produced hot-plate and tail-flick antinociception when injected alone into the RVM. These data are consistent with the hypothesis that the antinociception produced by muscarinic stimulation of the RVM is mediated by an L-arginine/nitric oxide/cyclic GMP cascade.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7514222

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

1.  Behavioral effects of morphine and cocaine in M1 muscarinic acetylcholine receptor-deficient mice.

Authors:  Kelly A Carrigan; Linda A Dykstra
Journal:  Psychopharmacology (Berl)       Date:  2007-01-09       Impact factor: 4.530

2.  Rostral ventral medulla cholinergic mechanism in pain-induced analgesia.

Authors:  Robert W Gear; Jon D Levine
Journal:  Neurosci Lett       Date:  2009-08-20       Impact factor: 3.046

3.  Antagonism of the antinociceptive effect of nitrous oxide by inhibition of enzyme activity or expression of neuronal nitric oxide synthase in the mouse brain and spinal cord.

Authors:  Jessica Lack Cope; Eunhee Chung; Yusuke Ohgami; Raymond M Quock
Journal:  Eur J Pharmacol       Date:  2009-10-08       Impact factor: 4.432

4.  L-NAME causes antinociception by stimulation of the arginine-NO-cGMP pathway.

Authors:  I D Duarte; S H Ferreira
Journal:  Mediators Inflamm       Date:  2000       Impact factor: 4.711

5.  Medial prefrontal cortex nitric oxide modulates neuropathic pain behavior through mu opioid receptors in rats.

Authors:  Dorsa Raisian; Amir Erfanparast; Esmaeal Tamaddonfard; Farhad Soltanalinejad-Taghiabad
Journal:  Korean J Pain       Date:  2022-10-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.